Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349132 | 0.93 | GRIA2 (0.51) | ALDH1A1KDM4ELMNAGRIA2KCNH2 | |
| SCHEMBL1348981 | 0.87 | NR1H2 (0.42) | ALDH1A1KMT2APKMRAB9A | |
| SCHEMBL1348740 | 0.81 | CMA1 (0.45) | ALDH1A1KMT2APKMMAPTRAB9A | |
| SCHEMBL1348608 | 0.80 | MCL1 (0.43) | ALDH1A1MEN1KMT2APKMRAB9A | |
| SCHEMBL1348917 | 0.80 | GRIA2 (0.43) | ALDH1A1GRIA2KMT2ARAB9A | |
| SCHEMBL1348865 | 0.79 | NR1H2 (0.42) | — | |
| SCHEMBL15841731 | 0.78 | BCL9 (0.38) | ALDH1A1KMT2APKMRAB9A | |
| SCHEMBL1349212 | 0.78 | MMP2 (0.46) | ALDH1A1MEN1KMT2APKMRAB9A | |
| SCHEMBL15841773 | 0.78 | BCL9 (0.37) | ALDH1A1LMNAMEN1KMT2APKM | |
| SCHEMBL1348509 | 0.77 | PKM (0.37) | ALDH1A1KMT2APKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | claimed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | claimed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | claimed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | claimed |
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | NR1H2, NR1H3, NR1D2 | ALDH1A1 1243/4885KDM4E 2119/4885LMNA 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.